Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Total Current Liabilities (2023 - 2025)

CG Oncology (CGON) has disclosed Total Current Liabilities for 3 consecutive years, with $30.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities rose 44.31% year-over-year to $30.8 million, compared with a TTM value of $30.8 million through Dec 2025, up 44.31%, and an annual FY2025 reading of $30.8 million, up 44.31% over the prior year.
  • Total Current Liabilities was $30.8 million for Q4 2025 at CG Oncology, up from $30.5 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $30.8 million in Q4 2025 and bottomed at $10.0 million in Q1 2024.
  • Average Total Current Liabilities over 3 years is $20.8 million, with a median of $21.4 million recorded in 2024.
  • Peak annual rise in Total Current Liabilities hit 156.31% in 2025, while the deepest fall reached 44.31% in 2025.
  • Year by year, Total Current Liabilities stood at $14.3 million in 2023, then surged by 49.91% to $21.4 million in 2024, then skyrocketed by 44.31% to $30.8 million in 2025.
  • Business Quant data shows Total Current Liabilities for CGON at $30.8 million in Q4 2025, $30.5 million in Q3 2025, and $30.4 million in Q2 2025.